BioSpace News Archive

Amgen (NASDAQ:AMGN) today announced that Greg Friberg , vice president and global oncology therapeutic area head at Amgen, will participate in a fireside chat as part of the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, Feb. 12 at 12:30 p.m. ET .

VolitionRx Limited (NYSE AMERICAN: VNRX) (“Volition”), a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today that it is commencing an underwritten public o

- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2020 fourth quarter and full year financial results on Tuesday, February 23, 2021 , after the close of the financial markets. Company management will host a live audio webcast immediately following the announcement at 4:30 p.m. EST / 9:30 p.m. GMT

Inogen to Announce Fourth Quarter and Year End 2020 Financial Results on February 24 th , 2021

Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet ® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately.

- Fourth Quarter 2020 QINLOCK® Net Revenue of $19.5 Million and Full Year 2020 QINLOCK Net Revenue of $39.5 Million - - Top-line Results in INTRIGUE Phase 3 Study of QINLOCK in Patients with Second-line GIST Expected in the Second Half of 2021 - - Pipeline Candidates, Vimseltinib (DCC-3014), Rebastinib and DCC-3116, Continue to Advance with Significant Clinical Milestones Expected in 2021 -

KalVista Pharmaceuticals, Inc. announced that it intends to offer and sell 4,500,000 shares of its common stock in an underwritten public offering.

Q4 2020 net sales rise 36% CER to $571.2 million, exceeding outlook of ≥+32% CER, and adjusted diluted EPS grows 42% to $0.68 CER, exceeding outlook of ~$0.64-0.65 CER Full-year 2020 net sales increase 23% CER to $1.87 billion, exceeding outlook of ~+22% CER, and adjusted diluted EPS grows 52% to $2.17 CER, exceeding outlook of ~$2.13-2.14 CER

Core One Labs Inc. (CSE:COOL)(OTC PINK:CLABF)(Frankfurt::LD62) (WKN: A2P8K3) is pleased to announce that it has added video conference capabilities to its previously announced teleconference call scheduled for Wednesday, February 10, 2021 at 1:30 p.m. PST, 4:30 p.m. EST and 10:30 p.m. CET, with Dr. Robert E.W. Hancock, Chairman and Joel Shacker, CEO to discuss development and strategy.

Amedisys, Inc., announced that it will report results for the fourth quarter and year ended December 31, 2020, after the market closes on February 24, 2021.